Fate Therapeutics Inc
Fate Therapeutics Inc (FATE) Options Open Interest
FATE options open interest is 5,559 contracts. The 2-week average daily volume is 104 contracts across the chain.
Read more
Monitoring FATE open interest helps you see where real money is positioned on Fate Therapeutics Inc's options and which strikes are attracting the most commitment from traders. Fate Therapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor FATE options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising FATE options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Fate Therapeutics Inc to settle.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where FATE open interest is concentrated. Our scanner maps Fate Therapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Fate Therapeutics Inc's options open interest as the signal it is, not as an afterthought.
| 3.00 | — | 0.75 | 0.75 | 1,000% | +0.4231 | 141 |
| 4.00 | — | 1.00 | 1.00 | 1,000% | +0.1930 | 124 |
| 2.00 | 0.15 | 1.00 | 0.58 | 590% | +0.8515 | 43 |
| 0.50 | 1.55 | 2.55 | 2.05 | 1,000% | +1.0000 | 5 |
| 1.00 | 1.05 | 2.05 | 1.55 | 1,000% | +0.9912 | 5 |
| 2.00 | — | 0.35 | 0.35 | 1,000% | -0.2253 | 33 |
| 3.00 | 0.15 | 1.15 | 0.65 | 771% | -0.6420 | 16 |
| 4.00 | 1.05 | 2.05 | 1.55 | 910% | -0.8395 | 4 |
| 0.50 | — | 0.05 | 0.05 | 1,000% | -0.0000 | 0 |
| 1.00 | — | 1.00 | 1.00 | 1,000% | -0.0088 | 0 |
As of September 17, 2026
Follow the money
Track FATE open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→